FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate: 1X Liquid is an MPS-grade, ultra-filtered cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. Processed through a proprietary Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), it delivers approximately 5× cleaner media than conventional 0.22 µm-filtered formulations by particulate count — making it microchannel-safe from day one.

• Quadruple-stage nano-filtration: 0.1 µm (Pre-filtration I & III) + 0.04 µm (Pre-filtration II & Final Polish)
• Endotoxin: NMT 0.05EU/ml (USP <85> BET verified per lot)
• RPMI 1640 base formulation; pH 7.4 (USP <791>)
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm), USP <85>
• ISO Class 5 aseptic fill & finish; ISO 13485:2016 QMS manufacturing
• Mycoplasma-controlled via sub-0.1 µm final filter stage
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.1–0.3 µm), subvisible debris, and endotoxin spikes that accumulate inside microchannels — corrupting biosensor readings, triggering inflammation in primary cultures, and shortening device lifetimes. FluxMPS™ eliminates these failure modes at the source.

Quadruple-stage filtration system

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate: 1X Liquid is processed through a four-stage serial filtration sequence reaching 0.04 µm — eliminating mycoplasma, subvisible particles, and bioburden that 0.22 µm filtration cannot address.

1. 1

   0.1 µm Pre-filtration I

   Removes large particulates and aggregates; protects downstream filter geometry and extends filter life.

2. 2

   0.04 µm Pre-filtration II

   Fine particulate and bacteria removal; retains mycoplasma (0.1–0.3 µm) — absent in standard 0.22 µm filtration.

3. 3

   0.1 µm Sterile-filtration I

   Second-pass redundancy for residual contaminants; ensures no breakthrough from Stage 1 reaches the final filter.

4. 4

   0.04 µm Sterile-filtration II — Final Polish

   Ultimate polishing; ISO Class 5 aseptic fill in a validated laminar-flow workstation under GMP-aligned conditions.

Designed for next-generation cell culture platforms

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate: 1X Liquid is validated for organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate contamination and endotoxin variation are unacceptable.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra-filtered variant is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm grade.

Lot-release quality parameters

Every production lot of FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate: 1X Liquid undergoes the complete quality-release battery below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers. All ingredient names and mg/L values reproduced from manufacturer specification. Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under ISO 13485:2016 QMS, with final packaging, testing, and customization at DiagnoCine Precision in Totowa, New Jersey, USA.

How DCP-RPMIG-P1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation.

Frequently asked questions

Common questions about FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate: 1X Liquid and MPS-grade cell culture media.

Supporting literature

Peer-reviewed publications supporting the scientific rationale for MPS-grade ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
4. Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
5. Kim S et al. (2012). Gut-on-a-chip microdevice replicates key functional features of the human intestine. Lab on a Chip, 12(12), 2165–2174. doi:10.1039/c2lc40074j
6. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
7. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
8. Schuster B et al. (2020). Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nature Communications, 11, 5271. doi:10.1038/s41467-020-19058-4
9. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175
10. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539